Worth a Shot? Evidence-Based Approach to Prescribing LAI Antipsychotic Medications-Presentation Slides

Presentation Slides

Pdf Summary

This document appears to be a summary of a presentation or article on the topic of the evidence-based approach to prescribing long-acting injectable (LAI) antipsychotic medications for the treatment of patients with serious mental illness, specifically schizophrenia. The presentation is part of the Clinical Support System for Serious Mental Illness (CSS-SMI) initiative implemented by the American Psychiatric Association (APA) and funded by the Substance Abuse and Mental Health Services Administration (SAMHSA). <br /><br />The document provides an overview of the various acronyms and definitions related to the topic, such as first-generation antipsychotics (FGA), second-generation antipsychotics (SGA), oral antipsychotics (OAP), and long-acting injectable antipsychotics (LAI). It also includes a list of learning objectives, which focus on incorporating APA guidelines, examining findings from peer-reviewed publications comparing oral and LAI antipsychotics, and contrasting research on first- and second-generation LAIs.<br /><br />The document goes on to summarize several literature reviews, studies, and observational data related to the use of LAIs and their benefits compared to oral antipsychotics. Key findings indicate that LAIs are associated with improved adherence, reduced risk of rehospitalization, decreased treatment discontinuation, lower hospitalization rates, and lower healthcare costs. LAIs also offer advantages in terms of convenience and decreased conflict related to medication reminders. The document highlights specific studies that show the effectiveness of LAIs in preventing hospital readmissions, reducing violence, and lowering mortality rates in patients with schizophrenia.<br /><br />The summary concludes by mentioning the difference in treatment patterns and outcomes between first- and second-generation LAIs and oral antipsychotics, with second-generation LAIs showing better treatment adherence and persistence. It also touches on the challenges of comparing LAIs and oral antipsychotics due to various factors and study designs.<br /><br />The document serves as a comprehensive summary of the evidence and findings discussed in the presentation or article, providing an overview of the potential benefits and advantages of prescribing LAI antipsychotic medications for patients with serious mental illness, particularly schizophrenia.

Keywords

evidence-based approach

LAI antipsychotic medications

serious mental illness

schizophrenia

APA guidelines

improved adherence

rehospitalization

healthcare costs

convenience

study designs